ClinicalTrials.Veeva
Menu

Find clinical trials for Non-Hodgkin Lymphoma in Hanyang, Seoul

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Lymphoma
B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma
Leukemia
Lymphoid Leukemia
B-Cell Chronic Lymphocytic Leukemia
Follicular Lymphoma

Non-Hodgkin Lymphoma trials near Hanyang, Seoul, KOR:

A Study of DR-0201 in Subjects With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of DR-0201 in adult patients with relapsed or refractory B-cell non...

Enrolling
B-cell Non Hodgkin Lymphoma
Drug: DR-0201

Phase 1

Dren Bio

Seoul, Korea, Republic of and 20 other locations

The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-99282 alone and in combination with anti-lymphoma...

Enrolling
Lymphoma, Non-Hodgkin
Drug: Obinutuzumab
Drug: CC-99282

Phase 1, Phase 2

Celgene
Celgene

Seoul, Korea, Republic of and 89 other locations

Determine MTD based on the safety and tolerability of AT101 and the RP2D for patients with recurrent or non-reactive B-cell NHL....

Enrolling
B-cell Non Hodgkin Lymphoma
Drug: AT101(Anti-CD19 Chimeric Antigen Receptor T cell)

Phase 1, Phase 2

AbClon

Seoul, Seoul, South Korea

is focused on patients with previously treated aggressive B-cell non-Hodgkin lymphoma whose cancer has stopped responding ...

Enrolling
B-Cell Non-Hodgkin Lymphoma (B-NHL)
Drug: Dexamethasone
Drug: Ifosfamide

Phase 3

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Seoul, Korea, Republic of and 60 other locations

B-cell Lymphoma is an aggressive and rare cancer of a type of immune cell (a white blood cell responsible for fighting infections). The purp-...

Enrolling
Non-Hodgkin Lymphoma
Drug: Pirtobrutinib
Drug: Ibrutinib

Phase 2

Genmab
Genmab

Seoul, Seoul Teugbyeolsi, Korea, Republic of and 74 other locations

receptor (CAR) T-cell therapy, targeting both cluster of differentiation (CD) CD19 and CD20 for the treatment of adult participants with B-Cell non...

Enrolling
Lymphoma, B-Cell
Lymphoma, Non-Hodgkin
Biological: JNJ-90014496

Phase 1

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Seoul, Korea, Republic of and 26 other locations

The main purpose of this study is to characterize safety and to determine the recommended phase 2 dose (RP2D) for JNJ-88998377 (Part A: Dose Escalati...

Enrolling
Lymphoma, Non-Hodgkin
Refractory B-Cell NHL
Drug: JNJ-88998377

Phase 1

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Seoul, Korea, Republic of and 18 other locations

bispecific antibody, in subjects with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) who have received 2 or mo...

Enrolling
B-cell Non Hodgkin Lymphoma
Follicular Lymphoma
Drug: AZD0486 IV

Phase 1

AstraZeneca
AstraZeneca

Seoul, Korea, Republic of and 28 other locations

ifosfamide, carboplatin, and etoposide (R-ICE) in pediatric and young adult participants with relapsed and refractory (R/R) mature B-cell non...

Enrolling
Mature B-Cell Non-Hodgkin Lymphoma
Drug: Ifosfamide
Drug: Rituximab

Phase 1, Phase 2

Roche
Roche

Seoul, Korea, Republic of and 23 other locations

participants with relapsed or refractory (R/R) diffuse-large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, transformed folli...

Active, not recruiting
Non-Hodgkin Lymphoma
Drug: Tocilizumab
Drug: Gemcitabine

Phase 3

Roche
Roche

Seoul, Korea, Republic of and 52 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems